Marker Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Marker Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Mar 17, 2022 |
| FY2021 | Dec 31, 2020 | $500.0K | Mar 17, 2022 |
| FY2019 | Dec 31, 2019 | $213.2K | Mar 12, 2020 |
| FY2019 | Dec 31, 2018 | $206.0K | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $183.1K | Mar 15, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.16M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($10.73M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($8.24M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($29.93M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($41.88M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($28.71M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($21.43M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($147.96M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($10.98M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($2.46M) | Mar 23, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.89M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($11.12M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($14.58M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($19.79M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($39.48M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($28.89M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($22.53M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($148.17M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($11.48M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($8.49M) | Mar 23, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.80M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $13.47M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $10.42M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.97M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $27.79M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $18.88M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $12.76M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $7.95M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $5.25M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.80M | Mar 23, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.01M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($10.91M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($16.44M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($26.97M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($27.28M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($20.03M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($18.28M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($14.48M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($8.44M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($6.51M) | Mar 23, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $375.0K | Mar 12, 2020 |
| FY2019 | Dec 31, 2018 | $147.7K | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 15, 2019 |
| FY2013 | Dec 31, 2013 | $218.6K | Apr 17, 2014 |
| FY2012 | Dec 31, 2012 | $218.6K | May 15, 2013 |
| FY2011 | Dec 31, 2011 | $218.6K | Apr 16, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.07M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $22.02M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $17.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $34.42M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $68.14M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $45.61M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $46.36M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $62.14M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $5.18M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $7.92M | Mar 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.27M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $3.46M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $3.07M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.82M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $24.15M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $18.27M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $2.27M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $2.80M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $1.52M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.74M | Mar 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.80M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $18.56M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $14.05M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $19.60M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $43.99M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | $27.34M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $44.09M | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | $59.34M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $3.66M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $6.18M | Mar 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($459.18M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($447.02M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($436.29M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($428.05M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($398.12M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($356.24M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($327.53M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($306.11M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($157.42M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($145.82M) | Mar 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.07M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $19.19M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $15.11M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.78M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $42.35M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $21.35M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $43.90M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $61.75M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $5.13M | Mar 15, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 17, 2022 |
| FY2017 | Dec 31, 2017 | (1) | Mar 23, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 23, 2018 |
| FY2016 | Dec 31, 2015 | (9) | Mar 14, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 17, 2022 |
| FY2017 | Dec 31, 2017 | (1) | Mar 23, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 23, 2018 |
| FY2016 | Dec 31, 2015 | (9) | Mar 14, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.70M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 10.70M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 8.90M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 8.40M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 8.30M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 50.70M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 45.70M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 45.40M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 10.60M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 8.40M | Mar 23, 2018 |